News

LaunchPad Medical Wins a $2.5 Million NIH Grant to Improve Cranial Procedures

LaunchPad Medical, Inc. announced that it has been awarded a $2.5 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant (1R44NS115386) from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite®, its bone adhesive biomaterial technology, to improve cranial flap fixation procedures. Read more >>
Read more...

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced the publication of results from the double-blind, randomized, placebo-controlled Phase 2 trial assessing the safety and efficacy of lenabasum in 42 patients with diffuse cutaneous systemic sclerosis in Arthritis & Rheumatology. Read more >>
Read more...